GlassScriptPhysician profile
Elaine Cramer
NPI 1174221279
$9,277.19
in general payments reported to CMS, 2019-2025
52 companies · $1,178 in 2025
The $1,178 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $3,607 · 2024: $4,492 · 2025: $1,178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,596 · Long Term Medical Supply Or Device Loan: $1,196 · Education: $485.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,595.98 |
| Long Term Medical Supply Or Device Loan | $1,196.40 |
| Education | $484.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,671.45 | 2024-2025 | |
| Janssen Biotech, INC. | $955.99 | 2023-2025 | Rybrevant, Carvykti, Erleada |
| Daiichi Sankyo INC. | $558.48 | 2023-2025 | Enhertu |
| Merck Sharp & Dohme LLC | $442.28 | 2023-2024 | Keytruda, Lynparza, Welireg |
| Astellas Pharma US INC | $437.70 | 2023-2025 | Xospata, Padcev, Xtandi |
| Takeda Pharmaceuticals U.S.A., INC. | $392.25 | 2023-2025 | Fruzaqla, Ninlaro, Iclusig |
| Gilead Sciences, INC. | $376.87 | 2023-2024 | Trodelvy |
| Abbvie INC. | $374.72 | 2023-2024 | |
| Incyte Corporation | $293.45 | 2023-2024 | Jakafi, Monjuvi, Pemazyre |
| Astrazeneca Pharmaceuticals LP | $263.19 | 2023-2025 | Enhertu, Tagrisso, Lynparza |
| Pfizer INC. | $230.99 | 2023-2025 | |
| Eisai INC. | $206.33 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $168.08 | 2023-2025 | Opdivo, Opdualag |
| Lilly USA, LLC | $160.08 | 2023-2025 | Verzenio, Jaypirca, Retevmo |
| Seagen INC. | $157.82 | 2023 | Adcetris, Tivdak, Tukysa |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $153.01 | 2023 | Libtayo |
| Blueprint Medicines Corporation | $147.21 | 2023-2024 | Ayvakit |
| Celgene Corporation | $143.32 | 2023-2025 | Reblozyl |
| Amgen INC. | $137.29 | 2023-2024 | Lumakras |
| Ipsen Biopharmaceuticals, INC | $129.11 | 2023-2024 | Onivyde, Tazverik, Somatuline Depot |
| Genmab U.S., INC. | $123.85 | 2023-2024 | Epkinly |
| Jazz Pharmaceuticals INC. | $117.41 | 2023-2024 | Zepzelca |
| Bayer Healthcare Pharmaceuticals INC. | $117.04 | 2023-2024 | |
| Caris Mpi, INC. | $114.96 | 2025 | Mi Cancer Seek |
| Stemline Therapeutics INC. | $112.22 | 2023-2024 | Orserdu |
| Puma Biotechnology, INC. | $102.08 | 2023-2024 | Nerlynx |
| Pharmaessentia USA Corporation | $89.23 | 2023-2024 | Besremi |
| Emd Serono, INC. | $85.68 | 2024 | |
| Glaxosmithkline, LLC. | $85.07 | 2023-2024 | Zejula, Ojjaara |
| Taiho Oncology, INC. | $77.21 | 2023-2024 | |
| Karyopharm Therapeutics INC. | $67.04 | 2023 | Xpovio |
| Alexion Pharmaceuticals, INC. | $64.26 | 2023-2024 | Ultomiris |
| Novocure INC. | $59.38 | 2023-2025 | Optune Lua (Novottf-200t), Optune |
| Mirati Therapeutics, INC. | $57.73 | 2023-2024 | Krazati |
| Sumitomo Pharma America, INC. | $53.90 | 2023 | Orgovyx |
| Pharmacosmos Therapeutics INC. | $52.69 | 2023-2024 | Monoferric |
| Progenics Pharmaceuticals, INC. | $51.67 | 2023-2024 | Pylarify |
| Agios Pharmaceuticals, INC. | $49.38 | 2023 | Pyrukynd |
| Sun Pharmaceutical Industries INC. | $40.20 | 2023-2024 | Yonsa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.79 | 2023 | Gilotrif |
| Deciphera Pharmaceuticals INC. | $34.90 | 2024 | Qinlock |
| Tersera Therapeutics LLC | $34.06 | 2023 | Zoladex |
| Rigel Pharmaceuticals, INC. | $32.54 | 2023 | Tavalisse, Rezlidhia |
| Acrotech Biopharma INC. | $32.10 | 2023 | Beleodaq |
| Kyowa Kirin, INC. | $28.30 | 2023 | Poteligeo |
| Exelixis INC. | $28.13 | 2023 | Cabometyx |
| Genzyme Corporation | $26.98 | 2023 | |
| Genentech USA, INC. | $24.61 | 2023 | Gavreto, Alecensa, Rozlytrek |
| Recordati_rare_diseases_inc. | $24.05 | 2023 | Sylvant |
| Array Biopharma INC | $19.52 | 2024 | Braftovi, Tukysa, Mektovi |
| Sobi, INC | $17.77 | 2023 | |
| Chiesi USA, INC. | $15.82 | 2023 | Ferriprox |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elaine Cramer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.